Literature DB >> 8729877

Prophylactic and therapeutic efficacy of an avian antitoxin in ricin intoxication.

P V Lemley1, B S Thalley, D C Stafford.   

Abstract

This study was designed to demonstrate the efficacy in animals of a ricin antitoxin consisting of purified avian antibodies. Antitoxins consisting of avian antibodies have significant advantages when compared to conventional mammalian (e.g. horse) antibodies; (a) avian antibodies do not fix human complement, eliminating associated inflammatory reactions, and, (b) avian antibodies can be manufactured more economically. Ricin toxoid was injected into laying hens followed by collection of eggs bearing hyperimmune immunoglobulin. Immunoglobulin was extracted from yolks and purified by immunoaffinity chromatography. In a mouse model for toxin neutralization it was shown that immunoaffinity purified ricin antibodies could prevent ricin lethality. Furthermore, it was shown that passive antibody treatment leads to active ricin immunization in animals given lethal ricin doses. Highly purified avian antibodies, as developed in this study, should offer enhanced clinical effectiveness, greater safety, and reduced manufacturing costs when compared to other technologies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8729877

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  3 in total

1.  Distribution of, and immune response to, chicken anti-alpha Gal immunoglobulin Y antibodies in wild-type and alpha Gal knockout mice.

Authors:  W E Walsh; B E Anderson; D Ivancic; Z Zhang; J P Piccini; T G Rodgers; W Pao; J P Fryer
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  Ricinus communis intoxications in human and veterinary medicine-a summary of real cases.

Authors:  Sylvia Worbs; Kernt Köhler; Diana Pauly; Marc-André Avondet; Martin Schaer; Martin B Dorner; Brigitte G Dorner
Journal:  Toxins (Basel)       Date:  2011-10-24       Impact factor: 4.546

Review 3.  The evolving field of biodefence: therapeutic developments and diagnostics.

Authors:  James C Burnett; Erik A Henchal; Alan L Schmaljohn; Sina Bavari
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.